PCM
OBIO icon

Prelude Capital Management’s Orchestra BioMed OBIO Stock Holding History

Prelude Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,389
Closed -$52.7K – 1443
2026
Q1 		$52.7K Buy
+12,389
New +$52.7K ﹤0.01% 1124

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Prelude Capital Management's OBIO Position: Q2 2026 in Review

Prelude Capital Management sold out of Orchestra BioMed (OBIO) in Q2 2026, closing a stake of 12,389 shares — an estimated $52.7K sold.

Prelude Capital Management first reported a position in OBIO in Q1 2026 and held it in 1 quarter. The position peaked at $52.7K in Q1 2026. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Prelude Capital Management reported no remaining Orchestra BioMed position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 12,389 Orchestra BioMed shares in Q2 2026, an estimated $52.7K.
  • Prelude Capital Management first reported a position in Orchestra BioMed in Q1 2026 and held it in 1 quarter.
  • Prelude Capital Management's Orchestra BioMed position peaked at $52.7K in Q1 2026.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.